PIK3CA and posterior cortical atrophy: A first clinical trial with Copanlisib (BAY 80-6946), a potent pan-class I PI3K inhibitor, showed promising anti-tumor pharmacodynamic activity and clinical benefit in patients with advanced solid tumors, including PCa (NCT00962611) [95].